Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
Gyre picks up Cullgen for its degraders
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Gilead buys Arcellx before it’s over the finish line
2026’s first big oncology buyout is here.
Sensei finds Faeth
The company buys in a PI3Kα and mTOR combo.
Eikon steps down into Nasdaq
With a slashed valuation the newly listed biotech heads for phase 3.
